MSFT vs PFE: Which Is the Better Buy?
Side-by-side comparison of Microsoft Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Microsoft Corporation · Technology
$497.12
+41.3% upside to fair value
High Conviction
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
MSFT has more upside to fair value
(+41.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MSFT |
PFE |
| Current Price |
$497.12 |
$27.64 |
| Fair Value Estimate |
$702.35 |
$30.94 |
| Upside to Fair Value |
+41.3%
|
+12.0%
|
| Market Cap |
$3,691.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
18.3x
|
17.4x
|
| Price / Sales |
11.1x
|
2.5x
|
| Price / FCF |
55.1x
|
14.3x
|
| Revenue Growth YoY |
+17.7%
|
+2.6%
|
| Gross Margin |
67.9%
|
71.3%
|
| Operating Margin |
46.8%
|
25.1%
|
| Return on Equity |
33.2%
|
4.9%
|
| Dividend Yield |
0.73% |
6.22% |
| FCF Yield |
1.81%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings gr…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
MSFT |
PFE |
| Zone Low |
$526.76 |
$23.21 |
| Zone High |
$597.00 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|